To assess the effect of pyridoxamine (PM) on bone formation and health in older women with type 2 diabetes (T2D) by inhibiting advanced glycation end products (AGEs), which are known to impair bone health.
Key Findings:
P1NP increased by 23.0% in the PM group vs 4.1% in placebo (P = .056 between groups; 95% CI for PM: 9, 37).
BMD at the femoral neck increased significantly in the PM group (2.6%) compared to placebo (0.9%, P = .007).
HbA1c decreased more in the PM group (0.38%) compared to placebo (0.05%, P = .04).
No significant changes in bone resorption markers or SAF were observed.
Interpretation:
PM treatment may enhance bone formation and density in older women with T2D, alongside reducing HbA1c levels, indicating a potential therapeutic role in managing diabetic bone disease, but further studies are essential to confirm these findings.
Limitations:
Small sample size (n = 55) may limit generalizability.
Short duration of treatment (1 year) may not capture long-term effects.
Potential biases or confounding factors were not addressed.
Conclusion:
Pyridoxamine shows promise as a potential intervention to improve bone health in older women with T2D, warranting further research to confirm these findings.
by Aiden V Brossfield, Donald J McMahon, Jason Fernando, Beatriz Omeragic, Rukshana Majeed, Sanchita Agarwal, Grazyna E Sroga, Bowen Wang, Deepak Vashishth, Mishaela R Rubin
